NVP-2   Click here for help

GtoPdb Ligand ID: 8053

Synonyms: Compound 310 [US8778951] [2] | Example 93 [US8778951]
Compound class: Synthetic organic
Comment: NVP-2 is one of the compounds claimed in patent WO2011012661 [1]. NVP-2 is an inhibitor of the cyclin-dependent kinase CDK9. It was a preclinical lead compound.
PubChem CID 77201406 represents the compound without stereochemistry, and PubChem CID 66937006 has stereochemistry specified at only one of the chiral centers.
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 8
Hydrogen bond donors 3
Rotatable bonds 10
Topological polar surface area 104.12
Molecular weight 512.27
XLogP 3.71
No. Lipinski's rules broken 0
Click here for help
Canonical SMILES COCC(NC1CCC(CC1)Nc1ncc(c(c1)c1cccc(n1)NCC1(C#N)CCOCC1)Cl)C
Isomeric SMILES COC[C@H](N[C@@H]1CC[C@H](CC1)Nc1ncc(c(c1)c1cccc(n1)NCC1(C#N)CCOCC1)Cl)C
InChI InChI=1S/C27H37ClN6O2/c1-19(16-35-2)32-20-6-8-21(9-7-20)33-26-14-22(23(28)15-30-26)24-4-3-5-25(34-24)31-18-27(17-29)10-12-36-13-11-27/h3-5,14-15,19-21,32H,6-13,16,18H2,1-2H3,(H,30,33)(H,31,34)/t19-,20-,21-/m1/s1
1. Barsanti PA et al.. (2011)
Pyridine and pyrazine derivatives as protein kinase modulators.
Patent number: WO2011012661. Assignee: Novartis Ag. Priority date: 30/07/2009. Publication date: 03/02/2011.
2. Barsanti PA, Hu C, Jin J, Keyes R, Kucejko R, Lin X, Pan Y, Pfister KB, Sendzik M, Sutton J et al.. (2014)
Heteroaryl compounds and their uses.
Patent number: US8778951. Assignee: Novartis Ag. Priority date: 30/07/2009. Publication date: 15/07/2014.